Treatment of Moderate-to-Severe Pain in Hepatocellular Carcinoma with Transcutaneous Electrical Acupoint Stimulation: A Randomized Controlled Trial
Lu Zhu,Jing Li,Zhao-Qin Wang,Yun-Jia Gu,Guo-Na Li,Wen-Jia Wang,Guang-Bin Pen,Qi Li,Meng-Die Wu,Hui-Rong Liu,Yan Huang,Lu-Yi Wu
DOI: https://doi.org/10.2147/jpr.s456874
IF: 2.8319
2024-04-30
Journal of Pain Research
Abstract:Lu Zhu, 1, &ast Jing Li, 1, &ast Zhao-Qin Wang, 1, 2, &ast Yun-Jia Gu, 1 Guo-Na Li, 3 Wen-Jia Wang, 1 Guang-Bin Pen, 1 Qi Li, 1 Meng-Die Wu, 1 Hui-Rong Liu, 1, 2 Yan Huang, 1, 2 Lu-Yi Wu 1 1 Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 2 Shanghai Research Institute of Acupuncture and Meridian, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 3 School of Acupuncture, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Lu-Yi Wu, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, No. 110 Ganhe Road, Hongkou District, Shanghai City, 200437, People's Republic of China, Email Yan Huang, Shanghai Research Institute of Acupuncture and Meridian, Shanghai University of Traditional Chinese Medicine, No. 650 Wanping South Road, Xuhui District, Shanghai City, 200030, People's Republic of China, Email Objective: Moderate-to-severe pain is the most common clinical symptom in patients with hepatocellular carcinoma (HCC).This trial aimed to analyze the clinical efficacy of Transcutaneous electrical acupoint stimulation (TEAS) in patients of HCC with severe pain and provide a reliable reference for optimizing the clinical diagnostic and therapeutic strategies of HCC. Methods: A total of 104 eligible patients were randomly allocated to experimental and control groups in a ratio of 1:1.The treatment was administered for 1 week continuously. Patients in both groups were followed up 1 week after the end of the treatment.The primary outcome measure was the Numerical Rating Scale (NRS) score, whereas the secondary outcome measures included Brief Pain Inventory BPI-Q3, Q4, Q5 scores, analgesic dose, frequency of opioid-induced gastrointestinal side effects, Karnofsky Performance Status (KPS), Quality of Life Scale - Liver Cancer (QOL-LC), and Brief Fatigue Inventory (BFI) scores. Results: The NRS scores of experimental group was significantly lower after treatment and at the follow-up than baseline (average P < 0.01), there were also statistical differences between the groups at the above time points (average P < 0.01). BPI-Q3, -Q4, and -Q5 scores in the experimental group were decreased after treatment when compared with those before treatment (average P < 0.01). Furthermore, there were significant improvements of gastrointestinal side effects, KPS, QOL-LC and BPI in the experimental group after treatment, and the above results were statistically significant compared to the control group. Conclusion: 7-day TEAS treatment can significantly enhance the analgesic effect and maintain for the following week, also reduce the incidence of gastrointestinal side effects caused by opioids, and improve the quality of life of patients with moderate-to-severe HCC-related pain, which has reliable safety and certain clinical promotion value. Keywords: hepatocellular carcinoma pain, transcutaneous electrical acupoint stimulation, cancer pain, randomized controlled trial Hepatocellular carcinoma (HCC) is defined as a malignant tumor originating from hepatocytes and represents the most common subtype of primary liver cancer (PLC), with approximately 75–85% of PLC cases being attributed to HCC worldwide. The relative 5-year survival rate of patients with HCC is only 18%. 1 90% of HCC patients experience pain symptoms due to overgrowth of liver tumors, their invasion or infiltration of surrounding tissues, and their suppressive effects on the nociceptors of adjacent organs, most of these patients experience moderate to severe pain. 2,3 Persistent pain seriously affects the quality of life of patients, and can even accelerate the progression of HCC, increase the risk of death, and bring heavy economic pressure and mental burden to their families. 4 The three-step analgesic regimen formulated by the World Health Organization (WHO) is most widely used for treating moderate-to-severe pain in HCC in clinical settings. In particular, patients with moderate pain are treated with weak opioid drugs, mainly codeine (Step 2), whereas those with severe pain are treated with strong opioid drugs, mainly morphine and oxycodone (Step 3). 5 Long-term use of opioids may cause nausea, vomiting, constipation, lethargy, and respiratory depression, -Abstract Truncated-
clinical neurology